Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways

Doudican,Nicole  A.; Wen,Shih  Ya; Mazumder,Amitabha; Orlow,Seth  J.

doi:10.3892/or.2012.1977

Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways

Authors:
- Nicole A. Doudican
- Shih Ya Wen
- Amitabha Mazumder
- Seth J. Orlow
View Affiliations

Affiliations: The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA , New York University Cancer Institute, New York, NY, USA
Published online on: August 22, 2012 https://doi.org/10.3892/or.2012.1977
Pages: 1851-1858

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Persistent paraprotein production in plasma cells necessitates a highly developed rough endoplasmic reticulum (ER) that is unusually susceptible to perturbations in protein synthesis. This biology is believed to account for the exquisite sensitivity of multiple myeloma (MM) to the proteasomal inhibitor bortezomib (BTZ). Despite remarkable response rates to BTZ in MM, BTZ carries the potential for serious side-effects and development of resistance. We, therefore, sought to identify therapeutic combinations that effectively disrupt proteostasis in order to provide new potential treatments for MM. We found that sulforaphane, a dietary isothiocyanate found in cruciferous vegetables, inhibits TNFα-induced Iκβ proteasomal degradation in a manner similar to BTZ. Like BTZ, sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide (ATO), an agent with clinical activity in MM. ATO and sulforaphane co-treatment augmented apoptotic induction as demonstrated by cleavage of caspase-3, -4 and PARP. The enhanced apoptotic response was dependent upon production of reactive oxygen species (ROS) as demonstrated by glutathione depletion and partial inhibition of the apoptotic cascade after pretreatment with the radical scavenger N-acetyl-cysteine (NAC). Combination treatment resulted in enhanced ER stress signaling and activation of the unfolded protein response (UPR), indicative of perturbation of proteostasis. Specifically, combination treatment caused elevated expression of the molecular chaperone HSP90 (heat shock protein 90) along with increased PERK (protein kinase RNA-like endoplasmic reticulum kinase) and eIF2α phosphorylation and XBP1 (X-box binding protein 1) splicing, key indicators of UPR activation. Moreover, increased splicing of XBP1 was apparent upon combination treatment compared to treatment with either agent alone. Sulforaphane in combination with ATO effectively disrupts protein homeostasis through ROS generation and induction of ER stress to culminate in inhibition of protein secretion and apoptotic induction in MM. Our results suggest that sulforaphane deserves further investigation in combination with ATO in the treatment of MM.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin. 59:225–249. 2009.
2	Kumar S: Multiple myeloma - current issues and controversies. Cancer Treat Rev. 36(Suppl 2): S3–S11. 2010. View Article : Google Scholar : PubMed/NCBI
3	Chari A, Mazumder A and Jagannath S: Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics. 4:273–287. 2010.PubMed/NCBI
4	Cavaletti G: Bortezomib-induced peripheral neuropathy: facts and genes. Lancet Oncol. 12:120–121. 2011. View Article : Google Scholar : PubMed/NCBI
5	Lai E, Teodoro T and Volchuk A: Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology. 22:193–201. 2007. View Article : Google Scholar : PubMed/NCBI
6	Ron D and Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 8:519–529. 2007. View Article : Google Scholar : PubMed/NCBI
7	Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, Clark S and Ron D: IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature. 415:92–96. 2002. View Article : Google Scholar : PubMed/NCBI
8	Szegezdi E, Logue SE, Gorman AM and Samali A: Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7:880–885. 2006. View Article : Google Scholar : PubMed/NCBI
9	Redman BG, Flaherty L, Chou TH, al-Katib A, Kraut M, Martino S, Chen B, Kaplan J and Valdivieso M: A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. J Clin Oncol. 8:1269–1276. 1990.PubMed/NCBI
10	Funato T, Ishii T, Kanbe M, Scanlon KJ and Sasaki T: Reversal of cisplatin resistance in vivo by an anti-fos ribozyme. In Vivo. 11:217–220. 1997.PubMed/NCBI
11	Munshi NC: Arsenic trioxide: an emerging therapy for multiple myeloma. Oncologist. 6(Suppl 2): S17–S21. 2001. View Article : Google Scholar : PubMed/NCBI
12	Rousselot P, Larghero J, Labaume S, Poupon J, Chopin M, Dosquet C, Marolleau JP, Janin A, Brouet JC and Fermand JP: Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol. 72:166–171. 2004. View Article : Google Scholar : PubMed/NCBI
13	Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E and Barlogie B: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia. 16:1835–1837. 2002. View Article : Google Scholar : PubMed/NCBI
14	Binet F, Chiasson S and Girard D: Arsenic trioxide induces endoplasmic reticulum stress-related events in neutrophils. Int Immunopharmacol. 10:508–512. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, Duncan G, Wang L, Liu P, Cui H, Reddan JR, Yang BF and Wormstone IM: Arsenic trioxide initiates ER stress responses, perturbs calcium signalling and promotes apoptosis in human lens epithelial cells. Exp Eye Res. 85:825–835. 2007. View Article : Google Scholar
16	Tang CH, Chiu YC, Huang CF, Chen YW and Chen PC: Arsenic induces cell apoptosis in cultured osteoblasts through endoplasmic reticulum stress. Toxicol Appl Pharmacol. 241:173–181. 2009. View Article : Google Scholar : PubMed/NCBI
17	Brooks JD, Paton VG and Vidanes G: Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev. 10:949–954. 2001.PubMed/NCBI
18	Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc N, Tulliez J and Terce F: Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60:1426–1433. 2000.PubMed/NCBI
19	Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G and Hrelia P: Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis. 23:581–586. 2002. View Article : Google Scholar : PubMed/NCBI
20	Balasubramanain S, Chew YC and Eckert RL: Sulforaphane sup-presses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells. Mol Pharmacol. 80:870–878. 2011. View Article : Google Scholar : PubMed/NCBI
21	Mi L, Gan N and Chung FL: Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells. Carcinogenesis. 32:216–223. 2011. View Article : Google Scholar : PubMed/NCBI
22	Doudican NA, Bowling B and Orlow SJ: Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism. Leuk Res. 34:229–234. 2010. View Article : Google Scholar
23	Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL and Chen GQ: Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta. Leukemia. 21:1488–1495. 2007. View Article : Google Scholar : PubMed/NCBI
24	Doudican N, Rodriguez A, Osman I and Orlow SJ: Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res. 6:1308–1315. 2008. View Article : Google Scholar : PubMed/NCBI
25	Canestraro M, Galimberti S, Savli H, Palumbo GA, Tibullo D, Nagy B, Guerrini F, Piaggi S, Cine N, Metelli MR and Petrini M: Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 199:110–120. 2010. View Article : Google Scholar
26	Chou TC and Talaly P: A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem. 252:6438–6442. 1977.PubMed/NCBI
27	Chou TC and Talaly P: Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 4:450–454. 1983. View Article : Google Scholar
28	Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM and Walter P: IRE1 signaling affects cell fate during the unfolded protein response. Science. 318:944–949. 2007. View Article : Google Scholar : PubMed/NCBI
29	Manga P, Bis S, Knoll K, Perez B and Orlow SJ: The unfolded protein response in melanocytes: activation in response to chemical stressors of the endoplasmic reticulum and tyrosinase misfolding. Pigment Cell Melanoma Res. 23:627–634. 2010. View Article : Google Scholar : PubMed/NCBI
30	Feinman R, Siegel DS and Berenson J: Regulation of NF-κB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol. 2:162–166. 2004.
31	Maniatis T: A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 13:505–510. 1999. View Article : Google Scholar : PubMed/NCBI
32	Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC and Rosen ST: Characterization of the MM. 1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 31:271–282. 2003. View Article : Google Scholar : PubMed/NCBI
33	Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L and Neckers L: Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol. 22:8506–8513. 2002. View Article : Google Scholar : PubMed/NCBI
34	Zhang K and Kaufman RJ: The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology. 66:S102–S109. 2006. View Article : Google Scholar : PubMed/NCBI
35	Badr CE, Hewett JW, Breakefield XO and Tannous BA: A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS One. 2:e5712007. View Article : Google Scholar : PubMed/NCBI
36	Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, Preti HA, Kamble RT, Zu Y, Ballon DJ and Chang CC: Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res. 34:85–92. 2010. View Article : Google Scholar : PubMed/NCBI
37	Campbell RA, Sanchez E, Steinberg JA, Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida B, Said J and Berenson JR: Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol. 138:467–478. 2007. View Article : Google Scholar : PubMed/NCBI
38	Berenson JR, Matous J, Swift RA, Mapes R, Morrison B and Yeh HS: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 13:1762–1768. 2007. View Article : Google Scholar : PubMed/NCBI
39	Qi X and Mochly-Rosen D: The PKCdelta-Abl complex communicates ER stress to the mitochondria - an essential step in subsequent apoptosis. J Cell Sci. 121:804–813. 2008. View Article : Google Scholar : PubMed/NCBI
40	Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT, Huang W, Chang WC, Chang YS, Chen CC and Lai MD: Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem. 279:46384–46392. 2004. View Article : Google Scholar : PubMed/NCBI
41	Hayashi T, Saito A, Okuno S, Ferrand-Drake M, Dodd RL and Chan PH: Damage to the endoplasmic reticulum and activation of apoptotic machinery by oxidative stress in ischemic neurons. J Cereb Blood Flow Metab. 25:41–53. 2005. View Article : Google Scholar : PubMed/NCBI
42	Walter L and Hajnoczky G: Mitochondria and endoplasmic reticulum: the lethal interorganelle cross-talk. J Bioenerg Biomembr. 37:191–206. 2005. View Article : Google Scholar : PubMed/NCBI
43	Brewster JL, Linseman DA, Bouchard RJ, Loucks FA, Precht TA, Esch EA and Heidenreich KA: Endoplasmic reticulum stress and trophic factor withdrawal activate distinct signaling cascades that induce glycogen synthase kinase-3 beta and a caspase-9-dependent apoptosis in cerebellar granule neurons. Mol Cell Neurosci. 32:242–253. 2006. View Article : Google Scholar
44	Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA and Orlowski RZ: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 110:3281–3290. 2007. View Article : Google Scholar : PubMed/NCBI
45	Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS and Anderson KC: Antimyeloma activity of heat shock protein-90 inhibition. Blood. 107:1092–1100. 2006. View Article : Google Scholar : PubMed/NCBI
46	Shah JJ and Orlowski RZ: Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 23:1964–1979. 2009. View Article : Google Scholar : PubMed/NCBI
47	Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA and Talalay P: Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta. 316:43–53. 2002. View Article : Google Scholar
48	Miller WH Jr, Schipper HM, Lee JS, Singer J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893–3903. 2002.PubMed/NCBI